STOCK TITAN

[Form 4] Medifast, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Medifast Director Scott Schlackman received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and represent the right to receive an equivalent number of common shares.

Key details of the transaction:

  • The RSUs will fully vest on June 25, 2026
  • Shares are granted under the Amended and Restated 2012 Share Incentive Plan
  • Following the transaction, Schlackman owns 25,548.707 shares directly
  • The grant is part of annual director compensation

The Form 4 was filed through an attorney-in-fact, Jason L. Groves, on June 26, 2025, within the required reporting timeline for insider transactions.

Scott Schlackman, Direttore di Medifast, ha ricevuto 11.168 unità azionarie vincolate (RSU) il 25 giugno 2025, nell'ambito del Piano di Compensazione Differita per i Direttori della società. Le RSU sono state assegnate a costo zero e rappresentano il diritto a ricevere un numero equivalente di azioni ordinarie.

Dettagli principali della transazione:

  • Le RSU matureranno completamente il 25 giugno 2026
  • Le azioni sono concesse nell'ambito del Piano Incentivi Azionari 2012, modificato e aggiornato
  • Dopo la transazione, Schlackman possiede direttamente 25.548,707 azioni
  • La concessione fa parte della remunerazione annua del direttore

Il Modulo 4 è stato presentato tramite un procuratore, Jason L. Groves, il 26 giugno 2025, rispettando i termini di segnalazione previsti per le transazioni interne.

Scott Schlackman, Director de Medifast, recibió 11,168 unidades restringidas de acciones (RSU) el 25 de junio de 2025, como parte del Plan de Compensación Diferida para Directores de la empresa. Las RSU se otorgaron sin costo y representan el derecho a recibir un número equivalente de acciones comunes.

Detalles clave de la transacción:

  • Las RSU se consolidarán completamente el 25 de junio de 2026
  • Las acciones se conceden bajo el Plan de Incentivos de Acciones Enmendado y Restablecido de 2012
  • Tras la transacción, Schlackman posee directamente 25,548.707 acciones
  • La concesión forma parte de la compensación anual del director

El Formulario 4 fue presentado a través de un apoderado, Jason L. Groves, el 26 de junio de 2025, dentro del plazo requerido para reportar transacciones de personas con información privilegiada.

Medifast 이사 Scott Schlackman은 2025년 6월 25일 회사의 이사 지연 보상 계획의 일환으로 11,168개의 제한 주식 단위(RSU)를 받았습니다. RSU는 비용 없이 부여되었으며 동일한 수의 보통주를 받을 권리를 나타냅니다.

거래 주요 내용:

  • RSU는 2026년 6월 25일에 완전히 취득됩니다
  • 주식은 수정 및 재정비된 2012년 주식 인센티브 계획에 따라 부여되었습니다
  • 거래 후 Schlackman은 직접 25,548.707주를 보유하게 됩니다
  • 이번 부여는 연간 이사 보상의 일부입니다

Form 4 서류는 대리인 Jason L. Groves를 통해 2025년 6월 26일 제출되었으며, 내부자 거래 보고 기한을 준수했습니다.

Scott Schlackman, administrateur de Medifast, a reçu 11 168 unités d’actions restreintes (RSU) le 25 juin 2025, dans le cadre du Plan de Rémunération Différée des Administrateurs de la société. Les RSU ont été attribuées sans coût et représentent le droit de recevoir un nombre équivalent d’actions ordinaires.

Détails clés de la transaction :

  • Les RSU seront entièrement acquises le 25 juin 2026
  • Les actions sont attribuées dans le cadre du Plan d’Incentive d’Actions modifié et restitué de 2012
  • Après la transaction, Schlackman détient directement 25 548,707 actions
  • L’attribution fait partie de la rémunération annuelle des administrateurs

Le formulaire 4 a été déposé par un mandataire, Jason L. Groves, le 26 juin 2025, dans les délais requis pour les déclarations d’opérations d’initiés.

Scott Schlackman, Direktor von Medifast, erhielt am 25. Juni 2025 11.168 Restricted Stock Units (RSUs) im Rahmen des Deferred Compensation Plans für Direktoren des Unternehmens. Die RSUs wurden kostenfrei gewährt und stellen das Recht dar, eine entsprechende Anzahl von Stammaktien zu erhalten.

Wichtige Details der Transaktion:

  • Die RSUs werden am 25. Juni 2026 vollständig unverfallbar
  • Die Aktien werden im Rahmen des geänderten und neu gefassten Aktienanreizplans von 2012 gewährt
  • Nach der Transaktion besitzt Schlackman direkt 25.548,707 Aktien
  • Die Zuteilung ist Teil der jährlichen Vergütung des Direktors

Das Formular 4 wurde am 26. Juni 2025 durch einen Bevollmächtigten, Jason L. Groves, fristgerecht eingereicht, wie es bei Insider-Transaktionen erforderlich ist.

Positive
  • None.
Negative
  • None.

Scott Schlackman, Direttore di Medifast, ha ricevuto 11.168 unità azionarie vincolate (RSU) il 25 giugno 2025, nell'ambito del Piano di Compensazione Differita per i Direttori della società. Le RSU sono state assegnate a costo zero e rappresentano il diritto a ricevere un numero equivalente di azioni ordinarie.

Dettagli principali della transazione:

  • Le RSU matureranno completamente il 25 giugno 2026
  • Le azioni sono concesse nell'ambito del Piano Incentivi Azionari 2012, modificato e aggiornato
  • Dopo la transazione, Schlackman possiede direttamente 25.548,707 azioni
  • La concessione fa parte della remunerazione annua del direttore

Il Modulo 4 è stato presentato tramite un procuratore, Jason L. Groves, il 26 giugno 2025, rispettando i termini di segnalazione previsti per le transazioni interne.

Scott Schlackman, Director de Medifast, recibió 11,168 unidades restringidas de acciones (RSU) el 25 de junio de 2025, como parte del Plan de Compensación Diferida para Directores de la empresa. Las RSU se otorgaron sin costo y representan el derecho a recibir un número equivalente de acciones comunes.

Detalles clave de la transacción:

  • Las RSU se consolidarán completamente el 25 de junio de 2026
  • Las acciones se conceden bajo el Plan de Incentivos de Acciones Enmendado y Restablecido de 2012
  • Tras la transacción, Schlackman posee directamente 25,548.707 acciones
  • La concesión forma parte de la compensación anual del director

El Formulario 4 fue presentado a través de un apoderado, Jason L. Groves, el 26 de junio de 2025, dentro del plazo requerido para reportar transacciones de personas con información privilegiada.

Medifast 이사 Scott Schlackman은 2025년 6월 25일 회사의 이사 지연 보상 계획의 일환으로 11,168개의 제한 주식 단위(RSU)를 받았습니다. RSU는 비용 없이 부여되었으며 동일한 수의 보통주를 받을 권리를 나타냅니다.

거래 주요 내용:

  • RSU는 2026년 6월 25일에 완전히 취득됩니다
  • 주식은 수정 및 재정비된 2012년 주식 인센티브 계획에 따라 부여되었습니다
  • 거래 후 Schlackman은 직접 25,548.707주를 보유하게 됩니다
  • 이번 부여는 연간 이사 보상의 일부입니다

Form 4 서류는 대리인 Jason L. Groves를 통해 2025년 6월 26일 제출되었으며, 내부자 거래 보고 기한을 준수했습니다.

Scott Schlackman, administrateur de Medifast, a reçu 11 168 unités d’actions restreintes (RSU) le 25 juin 2025, dans le cadre du Plan de Rémunération Différée des Administrateurs de la société. Les RSU ont été attribuées sans coût et représentent le droit de recevoir un nombre équivalent d’actions ordinaires.

Détails clés de la transaction :

  • Les RSU seront entièrement acquises le 25 juin 2026
  • Les actions sont attribuées dans le cadre du Plan d’Incentive d’Actions modifié et restitué de 2012
  • Après la transaction, Schlackman détient directement 25 548,707 actions
  • L’attribution fait partie de la rémunération annuelle des administrateurs

Le formulaire 4 a été déposé par un mandataire, Jason L. Groves, le 26 juin 2025, dans les délais requis pour les déclarations d’opérations d’initiés.

Scott Schlackman, Direktor von Medifast, erhielt am 25. Juni 2025 11.168 Restricted Stock Units (RSUs) im Rahmen des Deferred Compensation Plans für Direktoren des Unternehmens. Die RSUs wurden kostenfrei gewährt und stellen das Recht dar, eine entsprechende Anzahl von Stammaktien zu erhalten.

Wichtige Details der Transaktion:

  • Die RSUs werden am 25. Juni 2026 vollständig unverfallbar
  • Die Aktien werden im Rahmen des geänderten und neu gefassten Aktienanreizplans von 2012 gewährt
  • Nach der Transaktion besitzt Schlackman direkt 25.548,707 Aktien
  • Die Zuteilung ist Teil der jährlichen Vergütung des Direktors

Das Formular 4 wurde am 26. Juni 2025 durch einen Bevollmächtigten, Jason L. Groves, fristgerecht eingereicht, wie es bei Insider-Transaktionen erforderlich ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SCHLACKMAN SCOTT

(Last) (First) (Middle)
C/O MEDIFAST, INC.
100 INTERNATIONAL DRIVE

(Street)
BALTIMORE MD 21202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MEDIFAST INC [ MED ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/25/2025 A 11,168(1) A $0 25,548.707 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These restricted stock units were granted under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated (the "Plan"), in connection with the payment of the reporting person's annual director fees. Each unit represents the right to receive one share of the Issuer's common stock. These shares are granted from the Issuer's Amended and Restated 2012 Share Incentive Plan and will vest in full on June 25, 2026.
Remarks:
/s/ Jason L. Groves, attorney-in-fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many restricted stock units (RSUs) did MED director Scott Schlackman receive on June 25, 2025?

Scott Schlackman received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of Medifast's Director's Deferred Compensation Plan. These units were granted in connection with his annual director fees.

When will Scott Schlackman's MED restricted stock units vest?

The restricted stock units granted to Scott Schlackman will vest in full on June 25, 2026, exactly one year after the grant date.

How many shares of MED stock does Scott Schlackman own after the June 25, 2025 RSU grant?

Following the reported RSU grant, Scott Schlackman beneficially owns 25,548.707 shares of Medifast (MED) common stock directly.

What type of compensation plan were MED director Schlackman's RSUs granted under?

The RSUs were granted under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated, and were issued from the company's Amended and Restated 2012 Share Incentive Plan.
Medifast

NYSE:MED

MED Rankings

MED Latest News

MED Latest SEC Filings

MED Stock Data

146.29M
10.69M
2.55%
83.35%
12.75%
Personal Services
Miscellaneous Food Preparations & Kindred Products
Link
United States
OWINGS MILLS